Taro shares plummet

By YIGAL GRAYEFF
November 17, 2005 23:22
2 minute read.

Shares of Taro Pharmaceutical Industries plummeted more than 25% on Thursday after it said that third-quarter net earnings almost halved and came in way below expectations. Taro, which was founded in Haifa, said that in the three months ending on September 30, net profit dropped to $2.1m. from $4m., earnings per diluted share fell to seven cents from 14 cents, and sales slipped to $72.5m. from $73.3m. Revenue in the 2004 period included contributions from over-the-counter product lines that Taaro divested earlier this year. Analyst expectations for EPS ranged from 25-31 cents and for revenue they ranged from $79.43m.-$82.8m., as compiled by Thomson Financial Network. Investors seem to have been horrified by the results and in morning trading on Nasdaq, shares plunged 26% to $16.17. Taro said earnings were hurt by price erosion and an increase in production costs, due to the strengthening of the Canadian dollar against the US dollar. Chairman Barrie Levitt said: "Our results reflect the competitive nature of the generic drug industry and our continuing investment in the development of proprietary and generic drugs." Nine-month net profit doubled to $12.6m. from $6.3m., diluted EPS rose to 42 cents from 21 cents, and sales rose to $225.3m. from $206.5m. Saifun Q3 net profit $10.8m. In its first earnings release following its listing on Nasdaq, Saifun Semiconductors said on Thursday that it made a third-quarter net profit of $10.8m. after making a loss of $4.4m. a year earlier. In the three months ending on September 25, pro forma earnings per diluted share were 43 cents compared with a net loss of 21 cents and revenue jumped to $17.9m. from $9.1m., boosted by a 124% rise in licensing revenue and a 15% increase in service revenue. Nine-month net profit was $35.9m. compared with a loss of $13.5m., pro forma diluted EPS was $1.41 after a loss 63 cents, and revenue soared to $61.9m. from $21.1m. Saifun, which made its Nasdaq debut last week, raised net proceeds of $121m. in its initial public offering after selling 5.75 million shares at $23.50 a share. In morning trading on Nasdaq, shares rose 3.3% to $32.76, reflecting a gain of almost 40% from its IPO price. The company develops a technology called nitride-read-only memory, or NROM, for the non-volatile semiconductor memory market. Non-volatile semiconductor memory devices retain stored information without a power source and are used in a variety of consumer electronic products.



More about:NASDAQ


Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS